Genetic test evaluation: Information needs of clinicians, policy makers, and the public

被引:120
作者
Burke, W
Atkins, D
Gwinn, M
Guttmacher, A
Haddow, J
Lau, J
Palomaki, G
Press, N
Richards, CS
Wideroff, L
Wiesner, GL
机构
[1] Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Atlanta, GA 30341 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Agcy Healthcare Res & Qual, Bethesda, MD USA
[4] NHGRI, Bethesda, MD 20892 USA
[5] Fdn Blood Res, Scarborough, ME 04074 USA
[6] Tufts Univ New England Med Ctr, Boston, MA 02111 USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Baylor Coll Med, Houston, TX 77030 USA
[9] NCI, Bethesda, MD 20892 USA
[10] Case Western Reserve Univ, Cleveland, OH 44106 USA
关键词
factor V; genetic markers; genetic predisposition to disease; genetic screening; genetics; phenylketonurias;
D O I
10.1093/aje/kwf055
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.
引用
收藏
页码:311 / 318
页数:8
相关论文
共 39 条
  • [1] [Anonymous], 1996, GUID CLIN PREV SERV
  • [2] BILLINGS PR, 1992, AM J HUM GENET, V50, P476
  • [3] ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN
    BLOEMENKAMP, KWM
    ROSENDAAL, FR
    HELMERHORST, FM
    BULLER, HR
    VANDENBROUCKE, JP
    [J]. LANCET, 1995, 346 (8990): : 1593 - 1596
  • [4] BRCA1 and BRCA2: a small part of the puzzle
    Burke, W
    Press, N
    Pinsky, L
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (11) : 904 - 905
  • [5] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2
    Burke, W
    Daly, M
    Garber, J
    Botkin, J
    Kahn, MJE
    Lynch, P
    McTierman, A
    Offit, K
    Perlman, J
    Petersen, G
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12): : 997 - 1003
  • [6] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer
    Burke, W
    Petersen, G
    Lynch, P
    Botkin, J
    Daly, M
    Garber, J
    Kahn, MJE
    McTiernan, A
    Offit, K
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11): : 915 - 919
  • [7] Shattuck lecture - Medical and societal consequences of the human genome project
    Collins, FS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (01) : 28 - 37
  • [8] The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
    De Stefano, V
    Martinelli, I
    Mannucci, PM
    Paciaroni, K
    Chiusolo, P
    Casorelli, I
    Rossi, E
    Leone, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) : 801 - 806
  • [9] Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
    Fodor, FH
    Weston, A
    Bleiweiss, IJ
    McCurdy, LD
    Walsh, MM
    Tartter, PI
    Brower, ST
    Eng, CM
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 63 (01) : 45 - 51
  • [10] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
    FORD, D
    EASTON, DF
    BISHOP, DT
    NAROD, SA
    GOLDGAR, DE
    HAITES, N
    MILNER, B
    ALLAN, L
    PONDER, BAJ
    PETO, J
    SMITH, S
    STRATTON, M
    LENOIR, GM
    FEUNTEUN, J
    LYNCH, H
    ARASON, A
    BARKARDOTTIR, R
    EGILSSON, V
    BLACK, DM
    KELSELL, D
    SPURR, N
    DEVILEE, P
    CORNELISSE, CJ
    VARSEN, H
    BIRCH, JM
    SKOLNICK, M
    SANTIBANEZKOREF, MS
    TEARE, D
    STEEL, M
    PORTER, D
    COHEN, BB
    CAROTHERS, A
    SMYTH, E
    WEBER, B
    NEWBOLD, B
    BOEHNKE, M
    COLLINS, FS
    CANNONALBRIGHT, LA
    GOLDGAR, D
    [J]. LANCET, 1994, 343 (8899) : 692 - 695